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Introduction
Influenza is unpredictable. It is a virus that
spreads globally and each season viruses emerge
with different virological, clinical and
epidemiological characteristics. Usually influenza
affects 5-20% [1] of the population but sometimes
a pandemic virus emerges which spreads on a
worldwide scale and infects a larger proportion of
the human population. 
On 11 June 2009 WHO announced that the
world was confronted with a pandemic virus –
pandemic (H1N1) 2009 virus. This virus was first
detected in two children in the United States in
March 2009 but had its epidemiological origins in
Mexico City in January-March 2009 [2]. The virus
quickly spread to the US and Canada, and then
further afield. In the European Union and EEA
countries, there are currently 9453 cases and four
deaths and globally there are now over 79,000
cases and 332 deaths (3 July 2009) [3].
The epidemiology of pandemic viruses is also
unpredictable. During the 20th century there
were three pandemics (1918-19, 1957-58 and
1968-69), each with its own virological, clinical
and epidemiological signature. For example, there
were an estimated 20-50 million deaths during the
1918-19 pandemic, 1-4 million during the 1957-58
pandemic and 1-4 million during the 1968-69
pandemic. 
This review deals with the first pandemic of the
21st century – the pandemic H1N1 2009 virus. As
information regarding the pandemic is continually
changing and being updated, the text is based on
knowledge up to 6 July 2009.
Social impact
The social impact of a pandemic is considerable.
There can be important morbidity in the
community which impacts the economy,
disrupting businesses and society in general.
Studies have estimated that the 1918-19 pandemic
led to a GDP loss (in percentage terms) of -16.9%
to 2.4%, the 1957-58 pandemic of -3.5% to 0.4%
and the 1968-69 pandemic of -0.4% to -1.5% [4]. 
Another feature of past pandemics is that they
do not affect all age groups in the same way: the
1918-19 pandemic mainly affected young adults,
the 1957-58 pandemic mainly affected children
and the 1968-1969 affected all age groups. The
current pandemic, which is generally
characterised by mild clinical symptoms, is mainly
affecting young persons aged 10-29 in Europe [5].
Public Health Response
The initial response to the current influenza
pandemic focused on information (e.g. providing
the latest information to reassure the population),
surveillance (clinical, epidemiological and
virological), containment (at a local level e.g.
closing schools and distribution of antivirals) and
preparations for the pandemic (e.g. preparing for
the distribution of antivirals and vaccination
campaigns).
The public health response will depend on the
spread of the pandemic virus in each country, so
surveillance is of critical importance. Pandemics
are usually associated with 2-4 pandemic waves
[6], so the public health response needs to plan for
the long-term, with peaks and ebbs in their
intensity.
Currently, the world is in the first wave of the
pandemic, with some countries being affected
earlier than others. Mexico [2], the US [7] and
Canada [8] have experienced or are experiencing
their first pandemic waves, the UK’s pandemic
wave is starting [9] and other countries in Europe
are still having sporadic but frequent cases. In each
country, the public health response and
surveillance system has been adapted to the
epidemiological situation, so there are currently
differing responses around the world.
Improvements to national and international
responses
On the surveillance front, the current pandemic
has highlighted the importance of local, national,
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regional and international surveillance, so that the
best public health decisions can be made.
Information needs to be better shared and made
more easily available to all levels of the public
health response chain (local, national, regional and
international).
Evolutionary studies have shown that the
pandemic virus comes from pigs and was
circulating in pigs for some time now [10]. Whilst
considerable efforts have been made to establish
and harmonise surveillance systems around the
world (e.g. in South East Asia, where most experts
thought the next pandemic would start), less
attention has been paid (globally) to pigs and the
interaction between pigs and humans. This is an
area that will need strengthening in the future.
Another point that has been highlighted during
the current pandemic is the paucity of evidence
regarding some of the preventive measures that
are being taken by countries to slow the spread of
the pandemic. For example, what is the effect of
putting tourists into quarantine or of closing
schools on the progression of the pandemic?
Considering there will be further waves in the
future and the consequences of these public
health interventions can be considerable (e.g. the
closing schools), this is another issue that needs
further attention.
Winter of 2009-2010
It is very likely that there will be at least two
waves of the pandemic H1N1 2009 virus. Some
countries saw the first wave at the start of 2009
(Mexico), or are currently experiencing a summer
wave (e.g. USA and Canada) and others will
experience it in the autumn or even the winter of
2009-2010. Countries in the Northern Hemisphere
that had a summer wave (e.g. USA), may
experience a second wave during the winter of
2009-2010.
Countries in Europe that are currently
experiencing sporadic cases (e.g. Italy and the
Netherlands) hope that the first wave starts as late
as possible, and public health containment
measures are being implemented in order to
postpone the first wave. The objective is to gain as
much time as possible before vaccines become
available (these are planned for August/September
2009). Some believe that as temperatures rise over
the summer, children stop going to school and
people are more often outdoors (e.g. on holiday)
the transmission of pandemic H1N1 2009
influenza virus will be slowed in Europe providing
extra time for the vaccination campaign.
Vaccination and antivirals
Antivirals play a very important role in the
public health response to the pandemic H1N1
2009 virus. They are being used to treat patients
and as part of containment strategies (prophylaxis
for family members and close contacts),
sometimes in combination with social distancing
strategies e.g. the closing of schools. Vaccination
will play an important role in the future when
vaccines become available in the autumn of 2009.
The main advantage of influenza vaccination is
that it is a public health measure that protects the
whole population. Influenza vaccines are effective
(70-90%), and reduce complications (e.g.
hospitalisations and deaths) [11]. The vaccines
under development are currently being tested but
their usage will need to be carefully monitored to
avoid a situation like in 1976 when a swine flu
vaccination program in the US had to be stopped
due to the emergence of side effects [12].
In comparison to previous pandemics, antivirals
are available this time round and this is a
considerable advantage. Many countries in Europe
have large stockpiles which cover 30% or more of
the population. Considering there will be a
number of pandemic waves, there will be
challenges with their distribution, the
management of supplies (so that we do not run
out of supplies) and possibly also with resistance
[13]. Whilst resistance was observed with the
H1N1 virus during the 2008-2009 season [14],
fortunately only one case has been observed in
Europe with the pandemic H1N1 2009 virus [15]. 
Conclusions
In conclusion, this is a challenging time for
public health in Europe. A pandemic raises many
very serious concerns, especially in the light of
the 1918-19 pandemic. Fortunately, the clinical
impact of the pandemic H1N1 2009 virus remains
mild [5] and Europe is much better prepared than
in previous pandemics [16]: pandemic plans and
antiviral drugs are available, there is a much better
health care infrastructure and a vaccine will
probably be available in the autumn of 2009.
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